Sonia Pernas, MD, PhD / Joyce O'Shaughnessy, MD / Hans Wildiers, MD, PhD - Case-Based Insights Into HER2-Low and -Ultralow Metastatic Breast Cancer: Elevating Patient Outcomes With ADCs

Please visit answersincme.com/860/98336099-replay to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in oncology discuss use of antibody-drug conjugates (ADCs) for patients with hormone-receptor (HR)–positive, HER2-low and -ultralow metastatic breast cancer. Upon completion of this activity, participants should be better able to: Describe the clinical significance of HER2-low and ultralow status in patients with metastatic breast cancer (mBC); Integrate testing strategies for HER2-low and ultralow mBC; Evaluate the clinical data for antibody drug conjugates (ADCs) in HER2-low and ultralow mBC; and Propose practical strategies to enhance the current and future use of ADCs in HER2-low and -ultralow mBC.